Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
Revenue of US$51.7 million in the second quarter of 2022Loss from operations of US$(17.9) million and adjusted EBITDA1 of US$6.5...
Cancer
Erasca to Present at the Morgan Stanley Global Healthcare Conference
SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
Sensus Healthcare to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BOCA RATON, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics...
Instil Bio to Present at Morgan Stanley Global Healthcare Conference
DALLAS, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing...
THE OVARIAN CANCER COMMUNITY DEMANDS BETTER OUTCOMES
Support, Research, and Saving Lives Remains Focus of First in Person Ovarian Cancer Canada Walk of Hope since 2019 File...
Sorrento Therapeutics to Participate in Morgan Stanley 20th Annual Global Healthcare Conference September 12-14
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Henry Ji, Ph.D.,...
Attralus Announces New Preclinical Data Demonstrating Novel Human Chimeric Antigen Receptor-Macrophages (CAR-M) for Potential Amyloid Removal at 18th International Symposium on Amyloidosis
Human CAR-M cells can be generated with the pan-amyloid reactive p5 peptide as the target amyloid recognition elementThis novel system...
Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative Colitis
PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model PNV-6005 - DSS-induced Ulcerative Colitis Model...
Iovance Biotherapeutics to Present Posters at ESMO 2022
SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel...
Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development...
Veru to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12th, 2022
MIAMI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
SAN DIEGO and REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in...
Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the...
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. and NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology...
Candel Therapeutics Upcoming Investor Conference Participation
NEEDHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing...
TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing with Runway Growth Capital
Initial $10 million draw extends cash runway to mid-2023SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq:...
Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022
SAN CARLOS, Calif., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative...
Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck
-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05,...
Alvotech Reports Update on Initial AVT02 Biologics License Application
REYKJAVIK, Iceland, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and...